about
First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressureLong-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study.Prevalence of self-reported early glaucoma eye drop bottle exhaustion and associated risk factors: a patient surveyEfficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.Ocular hypotensive efficacy and safety of a combined formulation of betaxolol and pilocarpine.Protocol for a randomised controlled trial to estimate the effects and costs of a patient centred educational intervention in glaucoma management.Improving adherence to glaucoma medication: a randomised controlled trial of a patient-centred intervention (The Norwich Adherence Glaucoma Study).Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic reviewThe relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity.Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United KingdomiStent as a Solo Procedure for Glaucoma Patients: A Systematic Review and Meta-Analysis.iStent with Phacoemulsification versus Phacoemulsification Alone for Patients with Glaucoma and Cataract: A Meta-Analysis.Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors.Impact of the introduction of generic latanoprost on glaucoma medication adherence.Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence.Impact of a health communication intervention to improve glaucoma treatment adherence. Results of the interactive study to increase glaucoma adherence to treatment trial.Patterns of adherence behaviour for patients with glaucoma.The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studiesAn assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite.Systematic review of educational interventions to improve glaucoma medication adherence.Selective Laser Trabeculoplasty vs. Fixed Combinations with Timolol in Practice: A Replacement Study in Primary Open Angle Glaucoma.Impossibility to eliminate observer effect in the assessment of adherence in clinical trials.User-centered Design of the eyeGuide: A Tailored Glaucoma Behavior Change Program.Brinzolamide-timolol suspension: acceptability and side effect profile.Microprocessor controlled compliance monitor for eye drop medicationEfficacy of repeated 5-fluorouracil needling for failing and failed filtering surgeries based on simple gonioscopic examination.Personalized behavior change program for glaucoma patients with poor adherence: a pilot interventional cohort study with a pre-post design
P2860
Q33534044-4D436CBA-59DD-4123-94B4-55A4A60570B2Q33687798-2410BBDE-FB3C-4241-B811-47056C2F5E01Q33812135-4192FDD4-8C27-41EB-8C35-1530877A02DAQ33857744-90AED6C2-FE5D-408D-952D-628D970099E5Q34211333-AC42155D-350D-4FB6-AEBA-26E8878F82A3Q34484441-EFF837A6-60DB-44E7-AB8A-D7DA83F6DB3CQ35127434-9BB5EEE4-5F26-4CEE-9D53-EA094E693C93Q35327935-4073E5D6-9E69-4C11-A550-1CCE198911FCQ35571666-60554CAB-2D57-4E72-AFF7-1F0673769754Q35592544-6FAF7673-DA7E-4DC8-8A6F-3715120025A2Q35644019-0C3B0BC2-13AB-4C22-A8C3-A38276173103Q35683969-30AEA3DE-C715-4D8C-83C8-875A49712975Q35862822-BC23762E-410D-4B87-A5B4-29B2824DF2B7Q35899865-02CAB2FC-C039-4971-96B7-44AF699BEDE9Q36344429-774FE022-AD26-4D0C-B7FA-E84A690E42E2Q36672290-2249823E-C099-44AC-B273-2EB8A816D866Q36764753-B657C5B5-2C46-47EC-9996-1BA7A8D9AB27Q37106339-12102DF7-E249-49C0-A09F-288478AA19D7Q37247297-82C5E01C-68F6-4A64-9F98-B3F4A5634EE2Q37711161-83028718-BB97-44E5-8A8D-9C91C6C7CD4EQ41464391-02DCEEBB-F241-47F8-BF21-52097C6A05FEQ41628187-954CF349-0987-458B-B8C2-FF302F702659Q41648189-FDD7CDB4-D617-42CD-8090-BC24E9EC6243Q41763868-84E3468C-1A32-4EF7-B428-6E9695B1FF01Q41851153-869F0306-D281-4BB8-836A-7414CE4FB55FQ41875381-525B2FDF-95EC-4147-B852-442411CBDE61Q56525913-E91D163B-9213-42BB-9C49-451DED5F4D35
P2860
description
1987 nî lūn-bûn
@nan
1987 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Compliance with topical timolol treatment.
@ast
Compliance with topical timolol treatment.
@en
Compliance with topical timolol treatment.
@nl
type
label
Compliance with topical timolol treatment.
@ast
Compliance with topical timolol treatment.
@en
Compliance with topical timolol treatment.
@nl
prefLabel
Compliance with topical timolol treatment.
@ast
Compliance with topical timolol treatment.
@en
Compliance with topical timolol treatment.
@nl
P2093
P1476
Compliance with topical timolol treatment.
@en
P2093
P304
P407
P577
1987-02-01T00:00:00Z